Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
← catalyst calendarNCT06712563 · readout in 117 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With IQVIA Pty Ltd.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
2,000estimated
Sites
7
Countries
Canada, Germany, Greece +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-17 | actual | When the study began enrolling |
| Primary completion | 2026-12-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-14 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Disease, Chronic Obstructive
Intervention
- Drug: Budesonide/glycopyrrolate/formoterol fumarate — also filed as BGF, Breztri
Primary outcome
what the primary-completion date above is the date OFCOPD Assessment Test (CAT)
measured 12 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed